These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19502531)

  • 1. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
    Lal R; Sukbuntherng J; Tai EH; Upadhyay S; Yao F; Warren MS; Luo W; Bu L; Nguyen S; Zamora J; Peng G; Dias T; Bao Y; Ludwikow M; Phan T; Scheuerman RA; Yan H; Gao M; Wu QQ; Annamalai T; Raillard SP; Koller K; Gallop MA; Cundy KC
    J Pharmacol Exp Ther; 2009 Sep; 330(3):911-21. PubMed ID: 19502531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.
    Cundy KC; Annamalai T; Bu L; De Vera J; Estrela J; Luo W; Shirsat P; Torneros A; Yao F; Zou J; Barrett RW; Gallop MA
    J Pharmacol Exp Ther; 2004 Oct; 311(1):324-33. PubMed ID: 15146029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.
    Cundy KC; Branch R; Chernov-Rogan T; Dias T; Estrada T; Hold K; Koller K; Liu X; Mann A; Panuwat M; Raillard SP; Upadhyay S; Wu QQ; Xiang JN; Yan H; Zerangue N; Zhou CX; Barrett RW; Gallop MA
    J Pharmacol Exp Ther; 2004 Oct; 311(1):315-23. PubMed ID: 15146028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease.
    Gerson LB; Huff FJ; Hila A; Hirota WK; Reilley S; Agrawal A; Lal R; Luo W; Castell D
    Am J Gastroenterol; 2010 Jun; 105(6):1266-75. PubMed ID: 20040914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
    Ishizuka T; Yoshigae Y; Murayama N; Izumi T
    Drug Metab Dispos; 2013 Nov; 41(11):1888-95. PubMed ID: 23946449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein.
    Ohura K; Nakada Y; Kotani S; Imai T
    J Pharm Sci; 2015 Sep; 104(9):3076-83. PubMed ID: 25953731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
    J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemistry and pharmacology of GABAB receptor ligands.
    Froestl W
    Adv Pharmacol; 2010; 58():19-62. PubMed ID: 20655477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity.
    Ohura K; Sakamoto H; Ninomiya S; Imai T
    Drug Metab Dispos; 2010 Feb; 38(2):323-31. PubMed ID: 19923255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baclofen novel gastroretentive extended release gellan gum superporous hydrogel hybrid system: in vitro and in vivo evaluation.
    El-Said IA; Aboelwafa AA; Khalil RM; ElGazayerly ON
    Drug Deliv; 2016; 23(1):101-12. PubMed ID: 24786486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.
    Nance PW; Huff FJ; Martinez-Arizala A; Ayyoub Z; Chen D; Bian A; Stamler D
    Spinal Cord; 2011 Sep; 49(9):974-80. PubMed ID: 21577221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the Oral Absorption of Ester-type Prodrugs].
    Ohura K
    Yakugaku Zasshi; 2020; 140(3):369-376. PubMed ID: 32115554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study.
    Okuda DT; Kantor D; Jaros M; deVries T; Hunter S
    Brain Commun; 2023; 5(1):fcad026. PubMed ID: 36861013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.